Meeting
2017 ASCO Annual Meeting
A phase 1 trial of NBTXR3 nanoparticles activated by intensity-modulated radiation therapy (IMRT) in the treatment of advanced-stage head and neck squamous cell carcinoma (HNSCC).
Authors
Christophe Le Tourneau
Institut Curie, Paris, France
Christophe Le Tourneau , Valentin Calugaru , Thomas Jouffroy , Jose Rodriguez , Caroline Hoffmann , Bernard Dodger , Victor Moreno , Emiliano Calvo
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Local-Regional Disease
Clinical Trial Registration Number
NCT01946867
Citation
J Clin Oncol 35, 2017 (suppl; abstr 6080)
DOI
10.1200/JCO.2017.35.15_suppl.6080
Abstract #
6080
Poster Bd #
68
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Phase I study of functionalized hafnium oxide nanoparticles (NBTXR3) activated by radiotherapy in cisplatin-ineligible locally advanced HNSCC patients.
First Author: Christophe Le Tourneau
Poster
2019 ASCO Annual Meeting
Hafnium oxide nanoparticles NBTXR3 activated by radiotherapy as a new therapeutic option for elderly/frail HNSCC patients.
First Author: Christophe Le Tourneau
Poster
2016 ASCO Annual Meeting
A phase 1 trial of vorinostat in combination with concurrent chemoradiation therapy in the treatment of advanced stage head and neck squamous cell carcinoma.
First Author: Theodoros Nicholas Teknos
Poster
2021 ASCO Annual Meeting
A phase I trial evaluating NBTXR3 activated by radiotherapy in combination with nivolumab or pembrolizumab in patients with advanced cancers.
First Author: Colette Shen